<i>Mamu-A*01</i>
            Allele-Mediated Attenuation of Disease Progression in Simian-Human Immunodeficiency Virus Infection

Zhang, Zhiqiang; Fu, Tong-Ming; Casimiro, Danilo R.; Davies, Mary‐Ellen; Liang, Xiaoping; Schleif, William A.; Handt, Larry; Tussey, Lynda; Chen, Minchun; Tang, Aimin; Wilson, Keith A.; Trigona, Wendy L.; Freed, Daniel C.; Tan, Charles; Horton, Melanie; Emini, Emilio A.; Shiver, John W.

doi:10.1128/jvi.76.24.12845-12854.2002

Cited by 105 publications

(92 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These investigations revealed a new association of Mauritian MHC haplotype and susceptibility/resistance to SHIV 89.6P infection. The association of particular MHC alleles with resistance of rhesus macaques to SIV and SHIV infection is well established [38][39][40][41][42][43]. Our results here extend the phenomenon to cynomolgus macaques of Mauritian origin.…”

Section: Introductionsupporting

confidence: 81%

Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: Influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV89.6P infection

Florese

Wiseman

Venzon

et al. 2008

Vaccine

View full text Add to dashboard Cite

Protection afforded by HIV Tat-based vaccines has differed in Indian rhesus and Mauritian cynomolgus macaques. We evaluated native Tat and Ad-HIVtat priming/Tat-boosting regimens in both species. Both vaccines were immunogenic. Only the Ad-tat regimen modestly reduced acute viremia in rhesus macaques after SHIV 89.6P challenge. Confounding variables uncovered in Mauritian macaques included significant associations of susceptibility to infection with MHC class IB and class II H2 and H5 haplotypes, and resistance to infection with class IB haplotypes H3 and H6. Although protection here was limited, Tat-based vaccines incorporating other HIV components have shown greater efficacy. Combination strategies should be further explored.

show abstract

Section: Introductionsupporting

confidence: 81%

Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: Influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV89.6P infection

Florese

Wiseman

Venzon

et al. 2008

Vaccine

View full text Add to dashboard Cite

show abstract

“…Recently published studies have suggested that Mamu A‫10ء‬ ϩ macaques fare better after SIV and recombinant SIV-HIV (SHIV) infections than Mamu A‫10ء‬ Ϫ animals do (79,115). Because each of our studies contained Mamu A‫10ء‬ ϩ animals, we examined the potential influence of Mamu A‫10ء‬ on our results.…”

Section: Fig 2 Antigen-specific T Cells In Immunized and Challenge mentioning

confidence: 99%

Novel Adeno-Associated Virus Vector Vaccine Restricts Replication of Simian Immunodeficiency Virus in Macaques

Johnson

Schnepp

Connell

et al. 2005

J Virol

View full text Add to dashboard Cite

Gene transfer vectors based on recombinant adeno-associated virus (rAAV) are simple, versatile, and safe. While the conventional applications for rAAV vectors have focused on delivery of therapeutic genes, we have developed the system for delivery of vaccine antigens. In particular, we are interested in generating rAAV vectors for use as a prophylactic human immunodeficiency virus type 1 (HIV-1) vaccine. To that end, we constructed vaccine vectors that expressed genes from the simian immunodeficiency virus (SIV) for evaluation in the monkey SIV model. After a single intramuscular dose, rAAV/SIV vaccines elicited SIV-specific T cells and antibodies in macaques. Furthermore, immunized animals were able to significantly restrict replication of a live, virulent SIV challenge. These data suggest that rAAV vaccine vectors induced biologically relevant immune responses, and thus, warrant continued development as a viable HIV-1 vaccine candidate.

show abstract

“…The increase in viral load indicated already that IL-15 treatment during acute infection may increase the normally slow progression of SIV infection in Mamu-A*01 ϩ rhesus macaques (45,46). We therefore followed the animals up to week 30.…”

Section: Il-15 Accelerated Disease Progression and Induced Meningoencmentioning

confidence: 99%

IL-15 Treatment during Acute Simian Immunodeficiency Virus (SIV) Infection Increases Viral Set Point and Accelerates Disease Progression despite the Induction of Stronger SIV-Specific CD8+ T Cell Responses

Mueller

Altork

et al. 2008

The Journal of Immunology

View full text Add to dashboard Cite

In this study, we examined the effect of in vivo treatment of acutely SIV-infected Mamu-A*01+ rhesus macaques with IL-15. IL-15 treatment during acute infection increased viral set point by 3 logs and accelerated the development of simian AIDS in two of six animals with one developing early minimal lesion SIV meningoencephalitis. Although IL-15 induced a 2- to 3-fold increase in SIV-specific CD8+ T cell and NK cell numbers at peak viremia and reduced lymph node (LN) SIV-infected cells, this had no impact on peak viremia and did not lower viral set point. At viral set point, however, activated SIV-specific CD8+ T cells and NK cells were reduced in the blood of IL-15-treated animals and LN SIV-infected cells were increased. Week 30 LN from IL-15-treated animals had significantly increased Gag-specific CD8+ T cell numbers, whereas total cell, lymphocyte, and CD4+ T cell numbers were reduced. IL-15 treatment significantly reduced anti-SIV Ab concentrations at week 3 and viral set point. IL-15 increased Ki-67+CD4+ T cells at week 1 of treatment and reduced blood CCR5+ and CD45RA−CD62L− CD4+ T cells. The frequency of day 7 Ki-67+CD4+ T cells strongly correlated with viral set point. These findings suggest that CD4+ T cell activation during acute infection determines subsequent viral set point and IL-15 treatment by increasing such activation elevates viral set point. Finally, IL-15-treated acutely SIV-infected primates may serve as a useful model to investigate the poorly understood mechanisms that control viral set point and disease progression in HIV infection.

show abstract

Mamu-A01* Allele-Mediated Attenuation of Disease Progression in Simian-Human Immunodeficiency Virus Infection

Cited by 105 publications

References 38 publications

Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: Influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV89.6P infection

Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: Influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV89.6P infection

Novel Adeno-Associated Virus Vector Vaccine Restricts Replication of Simian Immunodeficiency Virus in Macaques

IL-15 Treatment during Acute Simian Immunodeficiency Virus (SIV) Infection Increases Viral Set Point and Accelerates Disease Progression despite the Induction of Stronger SIV-Specific CD8+ T Cell Responses

Contact Info

Product

Resources

About

Mamu-A*01 Allele-Mediated Attenuation of Disease Progression in Simian-Human Immunodeficiency Virus Infection

Cited by 105 publications

References 38 publications

Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: Influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV89.6P infection

Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: Influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV89.6P infection

Novel Adeno-Associated Virus Vector Vaccine Restricts Replication of Simian Immunodeficiency Virus in Macaques

IL-15 Treatment during Acute Simian Immunodeficiency Virus (SIV) Infection Increases Viral Set Point and Accelerates Disease Progression despite the Induction of Stronger SIV-Specific CD8+ T Cell Responses

Contact Info

Product

Resources

About

Mamu-A01* Allele-Mediated Attenuation of Disease Progression in Simian-Human Immunodeficiency Virus Infection